Bankrate (RATE) Jumps 6.35% on February 15

Equities Staff |

Bankrate (RATE) was among the biggest gainers on the Russell 2000 for Monday February 15 as the stock popped 6.35% to $12.05, representing a gain of $0.72 per share. Some 1.18 million shares traded hands on 7,490 trades, compared with an average daily volume of 661,626 shares out of a total float of 99.38 million. The stock opened at $11.45 and traded with an intraday range of $12.07 to $11.31.

After today's gains, Bankrate reached a market cap of $1.2 billion. Bankrate has had a trading range between $15.80 and $8.87 over the last year, and it had a 50-day SMA of $12.46 and a 200-day SMA of $11.71.

Bankrate Inc and its subsidiaries own and operate an Internet-based consumer banking and personal finance network.

Bankrate is based out of New York, NY and has some 552 employees. Its CEO is Kenneth Esterow.

For a complete fundamental analysis analysis of Bankrate, check out’s Stock Valuation Analysis report for RATE. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…